Kornimate/medical-research-clean huggingface dataset:
microbial associations in periodontal health and disease

Conditions: Periodontitis; Periodontal Diseases

Summary: the purpose of this study is to determine the clinical and microbiological effects of systemically administered metronidazole alone or in combination with professional plaque removal on periodontally diseased patients.

major goals of periodontal research are to differentiate pathogenic from host compatible plaque microbiotas and to optimize treatments to convert the former to the latter. to this end, in the previous award period the composition of supra and subgingival plaques, the associations among species both within and between supra and subgingival plaques, and differences between plaques from healthy and diseased individuals were determined. one major finding was the frequent detection of anaerobic periodontal pathogens at low numbers in supragingival plaque of periodontally diseased and to a lesser extent healthy subjects. weekly professional supragingival plaque removal for 3 months in 18 periodontitis subjects demonstrated astonishing reductions in the subgingival microbiota which were maintained for 9 months after cessation of the professional program. the composition of the microbiota at 12 months in these subjects was similar to that found in periodontal health. in another of our studies, systemically administered metronidazole produced similar effects. thus, in sa1 a 2 year randomized clinical trial will be performed comparing the effects of 1) srp alone or in combination with 2) weekly professional supragingival plaque removal, 3) systemically administered metronidazole or 4) a combination of the 2 on clinical parameters and supra and subgingival plaque composition. 200 periodontitis patients will receive srp under local anaesthesia and will be randomly assigned to the 4 treatment groups. all subjects will be evaluated clinically and for supra and subgingival plaque composition at 2 weeks, 3, 6, 12, 18 and 24 months. supra and subgingival plaque samples will be taken separately from the mesial aspect of each tooth and evaluated individually for their content of 40 bacterial species using checkerboard dna-dna hybridization providing over 3.6 million bacterial counts. the results will determine if the beneficial effect of the individual therapies persist beyond one year and whether combined treatment produces even greater benefit to the patient.

Eligibility criteria:
inclusion: * \> 35 years of age * \> 20 teeth * \> 5% sites (approx. 8 sites) with pocket depth \> 4 mm and / or 5% sites with attachment level \> 4 mm exclusion: * \> 50% of sites with pocket depth or attachment level \> 4 mm * pregnancy or lactation * periodontal or antibiotic therapy in the previous 12 months * any systemic condition which might influence the course of periodontal disease or treatment (e.g. diabetes, aids) * any systemic condition which requires antibiotic coverage for routine periodontal procedures (e.g. heart conditions, joint replacements etc.) * any known allergy to metronidazole
ivus chip upp registry

Conditions: Coronary Artery Disease; Coronary Artery Disease Risk High; Complex Coronary Artery Disease

Summary: the ivus chip upp registry is a prospective, observational, multicenter, single-arm registry. a total of 1010 patients with complex coronary lesions will be enrolled in up to 2 years, with at least 500 men and women. all patients will be treated with ivus-guided pci.

objective is to describe in a united states population the clinical efficacy and safety of an ivus-guided approach in patients who self-identify within a census-defined minority undergoing pci of complex coronary lesions, as well as clinical outcomes up to 2 years.

Eligibility criteria:
inclusion criteria: 1. the patient must be ≥18 years of age and self-identify within a us census-defined minority 2. patients with an indication for pci of at least one lesion satisfying any of the following criteria: 1. angiographic heavy calcification 2. ostial lesions 3. true bifurcation lesions involving side-branches \&gt;2.5mm 4. left main lesions 5. chronic total occlusion 6. in-stent restenosis 7. long-lesions (estimated stent length \&gt; 28mm) or patient with an indication for pci for any lesion and in need for elective mechanical circulatory support assisted pci 3. presenting with silent ischemia, stable angina, unstable angina or non-st-elevation acute coronary syndrome (nste-acs) 4. all lesions must be suitable for treatment with fda-approved contemporary generation drug eluting stents or drug-coated balloons 5. the patient is willing and able to cooperate with registry procedures and follow-up until registry completion 6. subject is able to confirm understanding of risks, benefits and treatment alternatives and he/she (or an authorized legal representative) provides informed consent prior to any protocol-related procedure, as approved by the appropriate irb exclusion criteria: 1. st-elevation myocardial infarction or cardiogenic shock within prior 7 days 2. known untreated severe valvular heart disease 3. contraindication on the use of ivus (i.e. extreme vessel tortuosity) 4. requiring pci in a diseased aorto-coronary bypass 5. known contraindication or hypersensitivity to anticoagulants 6. absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to antiplatelet drugs, including both aspirin and p2y12 inhibitors 7. non-cardiac co-morbidities with a life expectancy less than 1 year 8. a patients that is currently participating in a clinical trial that has not yet reached its primary endpoint cannot be included in this registry. a patient may only be enrolled in this registry once.

Keywords: pci intravascular ultrasound chip ivus-guidance
menorrhagia, dysmenorrhea and iron deficiency among young women soldiers and effect on activity

Conditions: Menorrhagia; Dysmenorrhea; Iron Deficiency Anemia

Summary: as combat women soldiers are required to more intensive daily activity the investigators believe that the impact of menorrhagia, dysmenorrhea and its clinical consequence (as characterized by, anemia iron deficiency and reduced quality of life)) on personal performance will be more significant in combat women soldiers compared to non-combat women soldiers. using cohorts from the same environment will enable the investigators to better study the effect of menorrhagia and dysmenorrhea eliminating other uncontrolled factors, such as nutrition. the study does not include any intervention.


Eligibility criteria:
inclusion criteria: * women soldiers in the participating units exclusion criteria: * lack of consent
correlation among various olga and olgim stages, digestive symptom scores, and acupuncture treatment in patients with chronic atrophic gastritis

Conditions: Chronic Atrophic Gastritis (CAG)

Summary: brief summary template for the study: the goal of this observational study is to examine the relationship between digestive symptom scores, serum pepsinogen indices, and histopathological olga and olgim systematic staging of the gastric mucosa in patients with chronic atrophic gastritis(cag), aiming to determine the degree of correlation between clinical manifestations, non-invasive laboratory tests, and the gold standard of diagnostic histopathology.to evaluate the comprehensive therapy, readiness and acceptance of acupuncture, utilization rates of various acupuncture therapies, self-assessed efficacy of acupuncture, and endoscopic histopathological alterations in patients with cag.according to the aforementioned study, it is anticipated to enhance the optimization of acupuncture clinical research protocols for chronic atrophic gastritis, improve treatment efficacy, and offer more effective and rational therapy alternatives for patients.the main question it aims to answer is: to determine if the outcomes of combined serologic testing of symptoms in patients with cag can serve as a method for monitoring disease development and if long-term follow-up can be supported？ a group of participants with recorded gi symptom scores and blood pepsinogen levels will respond to online survey questions regarding the severity of their chronic atrophic gastritis progression over the course of 1 year.

this study is a multicenter cross-sectional pilot survey

Eligibility criteria:
inclusion criteria: * fulfill the diagnostic criteria for chronic atrophic gastritis; * individuals aged 18 to 75 years, irrespective of gender; * capable of comprehending and consenting to participate in this study by signing the informed consent form. exclusion criteria: * autoimmune gastritis (type a chronic atrophic gastritis); * patients diagnosed with gastroesophageal reflux disease (gerd) by endoscopy or other examinations or patients diagnosed with high-grade intraepithelial neoplasia by upper gastrointestinal endoscopy and gastric mucosal biopsy pathology; * patients with confirmed or unable to exclude malignant tumors, especially esophageal and gastric cancers; patients with other upper gastrointestinal tract pathologies such as peptic ulcer or barrett's esophagus; * those who cannot complete the questionnaire due to unconsciousness, inability to communicate normally or other reasons; those with incomplete information.

Keywords: chronic atrophic gastritis global overall symptom scale serum pepsinogen operative link for gastritis assessment operative link for gastric intestinal metaplasia assessment
paired assessment of two electromyographic neuromuscular monitors: stimpod nmx450x versus datex-ohmeda e-nmt

Conditions: Neuromuscular Manifestations

Summary: after anesthesia is induced, 2 emg toff devices will be placed on the patients arms, one on the right arm, the other on the left. there will be a randomization per dominant hand and nondominant hand for the placing of the devices. the devices are the stimpod nmx450x and the datex-ohmeda e-nmt.


Eligibility criteria:
inclusion criteria: * adult patients (18 years old and above) * undergoing general anaesthesia for noncardiac surgery requiring the use of a neuromuscular blocking agent. exclusion criteria: * use of different types of neuromuscular blocking agents for the same patient within the same surgical procedure. * known neuromuscular diseases/syndromes judged to condition accurate neuromuscular monitoring. * known acute or chronic hepatic disease.
topical timolol 0.5% solution for proliferating infantile hemangiomas

Conditions: Hemangioma; Infant

Summary: the purpose of this study is to learn about a new potential use for topical timolol 0.5% aqueous solution that may help treat small uncomplicated infantile hemangiomas. this study would examine whether topical timolol could be a potential therapy.

at the first visit, subjects will fill out a questionnaire that asks about the child's history and the hemangioma. photographs and measurements will be taken at this and each subsequent visit. at the first visit, subjects will have a physical exam, including vital signs, height and weight. an ekg will also be done. study drug will be dispensed and instructions given. half of the subjects will receive a placebo. this is a blinded randomized study. follow-up visits will be weekly for the first two weeks (three visits total including the first visit), then monthly until the study is over. photographs and measurements will again be taken at each visit. subjects will be asked to evaluate the size and the color of the hemangioma against the first photographs and fill out forms regarding any changes in behavior and asked about any side effects.

Eligibility criteria:
inclusion criteria: infants 1 month to 8 months of age with infantile hemangioma (ih) that are 3 cm or less on the scalp, trunk, or extremities. exclusion criteria: 1. subjects with facial, genital, perianal, hand, finger, feet, or toe ih 2. subjects with phaces (plaque-like hemangioma on the face awaiting imaging) syndrome (proven) or suspected phaces . 3. subjects with ih measuring more than 3cm in size or ulcerated. 4. children with a history of hypersensitivity to beta blockers. 5. children with a personal history of asthma. 6. children with known renal impairment. 7. children with known cardiac conditions that may predispose to heart block 8. personal history of hypoglycemia 9. children on medications that may interact with beta blockers

Keywords: topical 0.5% timolol infantile hemangioma (ih)
epigenetic evaluation of hat/hdac activity in pbmc from patients with clinically isolated syndrome

Conditions: Demyelinating Autoimmune Diseases, CNS

Summary: the aim of the study is to compare the enzymatic activity of hats and hdacs in peripheral blood mononuclear cell (pbmc) of patients with a clinically isolated syndrome (cis group) and healthy controls (control group).

multiple sclerosis (ms) is an autoimmune inflammatory demyelinating disease of the central nervous system (cns). clinically isolated syndrome (cis) is often a sign of multiple sclerosis and the term refers to the first episode of neurologic symptoms experienced by a patient. possible presentations of cis include optic neuritis, a brain stem and/or cerebellar syndrome, a spinal cord syndrome, or occasionally cerebral hemispheric dysfunction. an accurate diagnosis at this time is important because people with a high risk of developing ms are encouraged to begin treatment in order to delay or prevent a second neurologic episode and, therefore, the onset of ms. the innate and adaptative immune systems play an important role in pathophysiology of ms, acting in interaction with environmental, genetic, and epigenetic factors. epigenetic modifications, such as dna methylation and histone modification, alter dna accessibility and chromatin structure, thereby regulating patterns of gene expression. these processes are crucial to normal development and differentiation of distinct cell lineages in the adult organism. histone acetylation, through the family of histone acetyl transferase (hat), is most consistently associated with promoting transcription. deacetylation of histones correlates with cpg methylation and the inactive state of chromatin. there are 4 classes of histone deacetylase enzymes (hdacs), with members capable of deacetylation of histones and/or other protein targets. acetylation homeostasis is a key regulator of both immune cell activation. of note, potent histone deacetylase inhibitors (hdaci) endowed with antiinflammatory and neuroprotective properties have been identified. efficacy of hdaci in experimental models of ms has been reported consistently. this study could provide information on the mechanisms involved.

Eligibility criteria:
inclusion criteria: * clinically isolated syndrome within the last 6 weeks (cis group) * healthy volunteer, free of any inflammatory disease (control group) * patient able to understand the reason of the study * signed informed consent exclusion criteria: * pregnancy * systemic corticosteroid therapy (\>1mg/kg) * immunosuppressive/immunomodulatory therapy (prior or ongoing) (cis group) * patient with ongoing infection (control group)

Keywords: histone deacetylases histone acetyltransferases
a retrospective review of gemcitabine, methylprednisolone cisplatin (gem-p) with or without rituximab in patients with relapsed/refractory diffuse large b cell lymphoma (dlbcl)

Conditions: Non-Hodgkins Lymphoma

Summary: there has been considerable international /national interest in the gem-p regimen for treatment of patients with relapsed/refractory lymphoma. currently, there is no accepted standard therapy for these patients. since the publication of our experience with this regimen (study with ccr ethics number 1857 closed to recruitment in july 2003:ng m, waters j, cunningham d et al, br j cancer 2005;92:1352-7), we have treated relapsed/refractory lymphoma patients with this regimen and would like to undertake a retrospective review of a sub-group of these patients with diffuse large b cell lymphoma (dlbcl). patients treated with gem-p with or without rituximab prior to march 2005 for refractory/relapsed dlbcl will be included in the analysis. accrual of eligible patients currently under follow-up will be performed in clinic at the time of next appointment. all patients accrued will give informed consent for retrospective case note review, after discussion with a study investigator and after receiving a study information sheet. all eligible patients identified from the pharmacy database, and will be consented at the time of the next clinic appointment, if they are agreeable for the retrospective case note review.


Eligibility criteria:
inclusion criteria: - a) age over 18 b) histological diagnosis of diffuse large b cell lymphoma c) patients who have received gemcitabine-cisplatin, methylprednisolone (gem-p) as per standard unit guidelines with or without rituximab for relapsed/refractory dlbcl. d) informed written consent exclusion criteria: * a) medical or psychiatric conditions that compromise the patient's ability to give informed consent b) hiv positive or aids related lymphoma
patient acceptance of whole body magnetic resonance angiography

Conditions: Atherosclerosis; Intermittent Claudication; MRI

Summary: investigation of how the patients experience whole body mra. after the wb-mra the patients will fill in a questionnaire, that contains questions about the wb-mra procedure and how the patient felt during the examination. we expect that the patients will report a high degree of satisfaction with the wb-mra procedure, with little discomfort.

wb-mra is performed in patients referred for conventional x-ray based angiography. the wb-mra is performed first in all patients. after both examinations are completed the patients will be asked to fill in a questionnaire containing questions about their experience of the 2 procedures. we will then compare the results for the procedures.

Eligibility criteria:
inclusion criteria: * symptomatic lower extremity ischemia (claudication, ischemic wounds) * referred to digital subtraction angiography (dsa) exclusion criteria: * renal insufficiency (gfr \< 30 ml/min) * contra-indications for mri-examination (claustrophobia, metal-implants, pacemaker) * dementia * pregnancy/lactation * allergy to gadolinium based mri contrast agents * acute disease

Keywords: magnetic resonance whole body angiography questionnaire
foot neuromodulation for overactive bladder in children

Conditions: Overactive Bladder

Summary: to determine the effects of electrical stimulation of the nerves in the foot on overactive bladder conditions in children.

bladder overactivity in the pediatric population presents a more challenging clinical situation than in adults after failure of medical therapy, as other treatments with proven efficacy such as botulinum injections and interstim sacral nerve stimulators are too invasive for the routine use in children. a non-invasive, effective way to improve overactive bladder in this population would have a great impact on a child's quality of life.

Eligibility criteria:
inclusion criteria: 1. children ages 5 to 16 years old without any specific neurological disorder or urinary tract infection, clinically diagnosed as idiopathic over active bladder (oab) 2. currently having oab symptoms, i.e. urinary frequency, urgency, or incontinence 3. having been assessed for and treated if applicable for behavioral etiologies of oab - holding urine too long, consuming excess caffeine or other bladder irritants. 4. having been assessed for and treated if applicable for constipation exclusion criteria: 1. patients with known neurological disorders which may be contributing to oab symptoms 2. patients found through history to have significant behavioral causes of oab including consumption of known bladder irritants and dysfunctional voiding. 3. patients with chronic constipation who are non-compliant with previous pharmacologic efforts to treat. 4. patients who are not adequately potty trained 5. patients who do not tolerate initial stimulation training session in the urology clinic upon enrollment 6. children with any implantable medical devices such as a pacemaker will be excluded from the study note: any patient currently taking medication such as an anti-muscarinic or a tricyclic antidepressant for overactive bladder at time of enrollment will be eligible to participate and will be continued on their usual medication and dosage throughout the study.
effects of chest physiotherapy in hyperventilation syndrome

Conditions: Hyperventilation

Summary: hyperventilation syndrome induce dyspnea and altered quality of life. the aim of this study is to assess the impact of chest physiotherapy on hyperventilation syndrome' symptoms


Eligibility criteria:
inclusion criteria: * patients addressed for hyperventilation syndrome * patient aged 18 years or over * patient able to consent and having sign a consent form exclusion criteria: * respiratory disease (copd, interstitial lung disease, bronchiectasis, cystic fibrosis, uncontrolled asthma) * patient with an inability to complete questionaires * refusal of participation * patient under tutorship or curatorship

Keywords: hyperventilation quality of life dyspnea nijmegen anxiety
behavioral activation teletherapy to increase physical activity

Conditions: Depression; Depressive Disorder; Depressive Symptoms; Depressive Episode

Summary: this is a pilot study of acceptability, feasibility, and preliminary efficacy of a brief, 10-session behavioral activation intervention delivered via teletherapy to increase physical activity and treat depressive symptoms.

this is a one-site, two-phase study that will use an initial group of individuals between the ages of 18 and 64 who have moderate to severe depressive symptoms and exercise less than 90 minutes a week. in both phases, participants will complete a total of 8 behavioral activation teletherapy sessions used to increase physical activity, followed by two biweekly booster sessions, for a total of 10 sessions. participants will also complete weekly assessments remotely for both phases of the study. the screening visit and final intervention session will be in-person, and all other visits will be via telehealth. participants will have the option to come to the clinic if they prefer. in the initial phase (n = 15), participants who completed the intervention will have the option to participate in a focus group, and participants who partially completed the intervention will have the option to participate in a semi-structured interview. the total duration of phase one is 14 weeks. this initial phase will allow the researchers to refine and optimize the intervention to be delivered in the second phase. in the second/pilot phase (n = 50), participants will complete a one-month and a two-month follow-up after the 10 intervention sessions. the total duration for phase two is 22 weeks. participants for both phases of the study will wear a fitbit during the duration of their study participation, in order to record step count.

Eligibility criteria:
inclusion criteria: * be18-64 years old; * able and willing to provide informed consent; * have moderate-to-severe depressive symptoms, with a phq-9 score ≥ 10; * insufficient moderate-to-vigorous physical activity (\< 90 minutes a week); * demonstrated interest in increasing physical activity; * have a smartphone. exclusion criteria: * have any current, past, or lifetime manic or hypomanic episode, psychosis, schizophrenia or schizophreniform disorder; * be currently experiencing active suicidal ideation (i.e. with suicidal thoughts, plan, and intent) or at a high risk for suicide during the course of the study, as designated by the pi; * have a medical condition that prohibits physical activity; be medically prohibited to exercise by primary care physician (pcp), ob-gyn (obstetrician-gynecologist) or study md. * be in current, active psychotherapy

Keywords: therapy teletherapy physical activity exercise